Stromal p16 expression is significantly increased in malignant ovarian neoplasms

Nara Yoon, Gun Yoon, Cheol Keun Park, Hyun Soo Kim

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Alterations in p16 protein expression have been reported to be associated with tumor development and progression. However, p16 expression status in the peritumoral stroma has been rarely investigated. We investigated the stromal p16 expression in ovarian neoplasms using immunohistochemistry, and differences in the expression status depending on the degree of malignancy and histological type were analyzed. This study included 24, 21, and 46 cases of benign, borderline, and malignant ovarian lesions, respectively, of which 29, 25, and 32 cases were serous, mucinous, and endometriosis-associated lesions. Most benign lesions showed negative or weak expression, whereas borderline lesions showed focal, moderate expression. Malignant lesions showed markedly elevated stromal p16 expression compared with benign or borderline lesions. There were significant differences in stromal p16 expression between benign and borderline lesions (P < 0.001) and between borderline and malignant lesions (P < 0.001). These significances remained when analysis was performed based on lesion classification as serous, mucinous, and endometriosisassociated. In contrast, differences in stromal p16 expression among the histological types were not significant. Stromal p16 expression in ovarian neoplasms was absent or weak in benign and focal, moderate in borderline lesions, whereas malignant lesions exhibited diffuse, moderate-to-strong p16 immunoreactivity. Our observations suggest that stromal p16 expression is involved in the development of ovarian carcinoma. Further studies are necessary to confirm our preliminary results.

Original languageEnglish
Pages (from-to)64665-64673
Number of pages9
JournalOncotarget
Volume7
Issue number40
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Ovarian Neoplasms
Endometriosis
Neoplasms
Immunohistochemistry
Carcinoma
Proteins

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Yoon, Nara ; Yoon, Gun ; Park, Cheol Keun ; Kim, Hyun Soo. / Stromal p16 expression is significantly increased in malignant ovarian neoplasms. In: Oncotarget. 2016 ; Vol. 7, No. 40. pp. 64665-64673.
@article{c49227e369b646d0a7ff809830e100d7,
title = "Stromal p16 expression is significantly increased in malignant ovarian neoplasms",
abstract = "Alterations in p16 protein expression have been reported to be associated with tumor development and progression. However, p16 expression status in the peritumoral stroma has been rarely investigated. We investigated the stromal p16 expression in ovarian neoplasms using immunohistochemistry, and differences in the expression status depending on the degree of malignancy and histological type were analyzed. This study included 24, 21, and 46 cases of benign, borderline, and malignant ovarian lesions, respectively, of which 29, 25, and 32 cases were serous, mucinous, and endometriosis-associated lesions. Most benign lesions showed negative or weak expression, whereas borderline lesions showed focal, moderate expression. Malignant lesions showed markedly elevated stromal p16 expression compared with benign or borderline lesions. There were significant differences in stromal p16 expression between benign and borderline lesions (P < 0.001) and between borderline and malignant lesions (P < 0.001). These significances remained when analysis was performed based on lesion classification as serous, mucinous, and endometriosisassociated. In contrast, differences in stromal p16 expression among the histological types were not significant. Stromal p16 expression in ovarian neoplasms was absent or weak in benign and focal, moderate in borderline lesions, whereas malignant lesions exhibited diffuse, moderate-to-strong p16 immunoreactivity. Our observations suggest that stromal p16 expression is involved in the development of ovarian carcinoma. Further studies are necessary to confirm our preliminary results.",
author = "Nara Yoon and Gun Yoon and Park, {Cheol Keun} and Kim, {Hyun Soo}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.11660",
language = "English",
volume = "7",
pages = "64665--64673",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "40",

}

Stromal p16 expression is significantly increased in malignant ovarian neoplasms. / Yoon, Nara; Yoon, Gun; Park, Cheol Keun; Kim, Hyun Soo.

In: Oncotarget, Vol. 7, No. 40, 01.01.2016, p. 64665-64673.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stromal p16 expression is significantly increased in malignant ovarian neoplasms

AU - Yoon, Nara

AU - Yoon, Gun

AU - Park, Cheol Keun

AU - Kim, Hyun Soo

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Alterations in p16 protein expression have been reported to be associated with tumor development and progression. However, p16 expression status in the peritumoral stroma has been rarely investigated. We investigated the stromal p16 expression in ovarian neoplasms using immunohistochemistry, and differences in the expression status depending on the degree of malignancy and histological type were analyzed. This study included 24, 21, and 46 cases of benign, borderline, and malignant ovarian lesions, respectively, of which 29, 25, and 32 cases were serous, mucinous, and endometriosis-associated lesions. Most benign lesions showed negative or weak expression, whereas borderline lesions showed focal, moderate expression. Malignant lesions showed markedly elevated stromal p16 expression compared with benign or borderline lesions. There were significant differences in stromal p16 expression between benign and borderline lesions (P < 0.001) and between borderline and malignant lesions (P < 0.001). These significances remained when analysis was performed based on lesion classification as serous, mucinous, and endometriosisassociated. In contrast, differences in stromal p16 expression among the histological types were not significant. Stromal p16 expression in ovarian neoplasms was absent or weak in benign and focal, moderate in borderline lesions, whereas malignant lesions exhibited diffuse, moderate-to-strong p16 immunoreactivity. Our observations suggest that stromal p16 expression is involved in the development of ovarian carcinoma. Further studies are necessary to confirm our preliminary results.

AB - Alterations in p16 protein expression have been reported to be associated with tumor development and progression. However, p16 expression status in the peritumoral stroma has been rarely investigated. We investigated the stromal p16 expression in ovarian neoplasms using immunohistochemistry, and differences in the expression status depending on the degree of malignancy and histological type were analyzed. This study included 24, 21, and 46 cases of benign, borderline, and malignant ovarian lesions, respectively, of which 29, 25, and 32 cases were serous, mucinous, and endometriosis-associated lesions. Most benign lesions showed negative or weak expression, whereas borderline lesions showed focal, moderate expression. Malignant lesions showed markedly elevated stromal p16 expression compared with benign or borderline lesions. There were significant differences in stromal p16 expression between benign and borderline lesions (P < 0.001) and between borderline and malignant lesions (P < 0.001). These significances remained when analysis was performed based on lesion classification as serous, mucinous, and endometriosisassociated. In contrast, differences in stromal p16 expression among the histological types were not significant. Stromal p16 expression in ovarian neoplasms was absent or weak in benign and focal, moderate in borderline lesions, whereas malignant lesions exhibited diffuse, moderate-to-strong p16 immunoreactivity. Our observations suggest that stromal p16 expression is involved in the development of ovarian carcinoma. Further studies are necessary to confirm our preliminary results.

UR - http://www.scopus.com/inward/record.url?scp=84994092807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994092807&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11660

DO - 10.18632/oncotarget.11660

M3 - Article

C2 - 27572321

AN - SCOPUS:84994092807

VL - 7

SP - 64665

EP - 64673

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -